Nicotinamide Riboside and Brain Energy in Healthy Adults
Official title: The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
Run by Massachusetts General Hospital · NCT07649161 · Data updated 2026-11-12
This study tests whether taking nicotinamide riboside by mouth for 2 weeks can change brain energy metabolism in healthy adults aged 18–65.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | December 2026 |
| Main results expected | September 2027 |
| Study ends | January 2028 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07649161 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18–65 without personal or family history of mood or psychotic disorders who can safely undergo MRI and comply with the protocol.
✕Probably not a fit
Individuals with significant medical conditions, psychiatric histories, pregnancy, or MRI contraindications may not benefit and may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm, open-label study using high-dose nicotinamide riboside to examine in vivo brain NAD+ and NADH levels and bioenergetic function. Participants will undergo phosphorus-31 MR spectroscopy at 7 Tesla before and after two weeks of NR treatment, serving as their own controls. The primary outcome is the NAD+ to NADH ratio in the brain, with secondary measures of overall brain energy metabolism. Up to 40 medically and psychiatrically healthy adults will be enrolled after screening for eligibility and safety. Exclusions include significant medical conditions, pregnancy, MRI contraindications, and current use of most medications or supplements.
Why it matters
Potential benefit: If successful, NR could reveal a way to influence brain energy metabolism in adults without psychiatric illness.
How similar studies have gone: Other studies using NR or similar NAD+ precursors have shown measurable effects on cellular energy processes in various tissues, though this exact brain-imaging approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults (between 18 and 65 years old) 2. Without a current psychiatric diagnosis assessed by a structured psychiatric interview at the screening/consent visit 3. Without a history of a psychotic disorder and/or mood disorder among parents, siblings, or children Exclusion Criteria: 1. Any current significant medical or neurological illness. 2. Diagnosis of diabetes mellitus (DM), uncontrolled hypertension (HTN), severe hypotension, coronary artery disease (CAD), metabolic syndrome, glaucoma, liver impairment, decreased renal function, respiratory disorders, and uncontrolled peptic ulcer disease. 3. Currently taking any other medications, including over-the-counter supplements except oral contraceptives for women and Tylenol as needed for pain or headache. 4. Currently pregnant or breastfeeding. Females of child-bearing age must be using an effective contraceptive method. 5. History of substance abuse or dependence. 6. Contraindication to MR scan (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal- containing IUDs) 7. Medical condition that would prevent blood draws, including current anti-coagulant or anti-aggregant therapy, tendency for abnormal scarring (e.g., keloids). 8. Difficulty in swallowing capsules.
Where it's running
-
Dauten Family Center for Bipolar Treatment Innovation
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Mohamed A Soliman, MD, MBA, PHD
- Email: msoliman5@mgb.org
- Phone: 617-726-5855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oura Ring validation for sleep using gold-standard sleep tests
This study tests how well the Oura Ring matches the gold-standard sleep test ( PSG ) in healthy adults and people with sleep apnea.
-
Magnetic field maps with NV sensors for non-invasive heart measurements
This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.
-
Cognitive Tasks and Models in a Large Online Sample
This study tests cognitive tasks and computational models in a large online group to see if these tools can help predict symptoms like hallucinations and delusions in the general population.
-
Single-dose study of DTI-117 given by injection in healthy adults
Researchers are testing a one-time dose of DTI-117 in healthy adult volunteers to see if it is safe and how it moves through the body.
-
Data-driven rural wellness interventions for vitality and endurance (DRIVE) pilot
This pilot test will see if personalized wellness coaching based on genomic, clinical, behavioral, and functional data can be feasibly delivered in a rural setting and improve cardiometabolic, cognitive, mental health, and functional outcomes over four months.
-
White potato meals and when you eat them: how timing changes blood sugar and appetite
This study tests how eating white potatoes with meals at different times affects blood sugar, hunger, and how much people eat later in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.